Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 302

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Open access
Stephenson, Kathryn E., Le Gars, Mathieu, Sadoff, Jerald, de Groot, Anne Marit, Heerwegh, Dirk, Truyers, Carla, Atyeo, Caroline, Loos, Carolin, Chandrashekar, Abishek, McMahan, Katherine, Tostanoski, Lisa H., Yu, Jingyou, Gebre, Makda S., Jacob-Dolan, Catherine, Li, Zhenfeng, Patel, Shivani, Peter, Lauren, Liu, Jinyan, Borducchi, Erica N., Nkolola, Joseph P., Souza, Morgana, Tan, Chen Sabrina, Zash, Rebecca, Julg, Boris, Nathavitharana, Ruvandhi R., Shapiro, Roger L., Azim, Ahmed Abdul, Alonso, Carolyn D., Jaegle, Kate, Ansel, Jessica L., Kanjilal, Diane G., Guiney, Caitlin J., Bradshaw, Connor, Tyler, Anna, Makoni, Tatenda, Yanosick, Katherine E., Seaman, Michael S., Lauffenburger, Douglas A., Alter, Galit, Struyf, Frank, Douoguih, Macaya, Van Hoof, Johan, Schuitemaker, Hanneke, Barouch, Dan H. · 2021 · JAMA

Abstract

Importance: Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective: To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses. Design, Setting, and Participants: Twenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; follow-up to assess durability will continue for 2 years. This study was conducted at a single clinical site in Boston, Massachusetts, as part of a randomized, double-blind, placebo-controlled phase 1 clinical trial of Ad26.COV2.S. Interventions: Participants were randomized to receive 1 or 2 intramuscular injections with 5 × 1010 viral particles or 1 × 1011 viral particles of Ad26.COV2.S vaccine or placebo administered on day 1 and day 57 (5 participants in each group). Main Outcomes and Measures: Humoral immune responses included binding and neutralizing antibody responses at multiple time points following immunization. Cellular immune responses included immunospot-based and intracellular cytokine staining assays to measure T-cell responses. Results: Twenty-five participants were randomized (median age, 42; age range, 22-52; 52% women, 44% male, 4% undifferentiated), and all completed the trial through the day 71 interim end point. Binding and neutralizing antibodies emerged rapidly by day 8 after initial immunization in 90% and 25% of vaccine recipients, respectively. By day 57, binding and neutralizing antibodies were detected in 100% of vaccine recipients after a single immunization. On day 71, the geometric mean titers of spike-specific binding antibodies were 2432 to 5729 and the geometric mean titers of neutralizing antibodies were 242 to 449 in the vaccinated groups. A variety of antibody subclasses, Fc receptor binding properties, and antiviral functions were induced. CD4+ and CD8+ T-cell responses were induced. Conclusion and Relevance: In this phase 1 study, a single immunization with Ad26.COV2.S induced rapid binding and neutralization antibody responses as well as cellular immune responses. Two phase 3 clinical trials are currently underway to determine the efficacy of the Ad26.COV2.S vaccine. Trial Registration: ClinicalTrials.gov Identifier: NCT04436276.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2021.3645

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 302

Metadata

Authors
Stephenson, K. E., Le Gars, M., Sadoff, J., de Groot, A. M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., Tostanoski, L. H., Yu, J., Gebre, M. S., Jacob-Dolan, C., Li, Z., Patel, S., Peter, L., Liu, J., Borducchi, E. N., Nkolola, J. P., Souza, M., Tan, C. S., Zash, R., Julg, B., Nathavitharana, R. R., Shapiro, R. L., Azim, A. A., Alonso, C. D., Jaegle, K., Ansel, J. L., Kanjilal, D. G., Guiney, C. J., Bradshaw, C., Tyler, A., Makoni, T., Yanosick, K. E., Seaman, M. S., Lauffenburger, D. A., Alter, G., Struyf, F., Douoguih, M., Van Hoof, J., Schuitemaker, H., & Barouch, D. H.
Venue
JAMA
Published
2021-04-20
Volume
325
Issue
15
Pages
1535
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W3133532742
Cited by
302
References
23
FWCI
20.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. https://app.cochat.ai/papers/10.1001/jama.2021.3645
The paper
Stephenson, K. E., Le Gars, M., Sadoff, J., de Groot, A. M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., Tostanoski, L. H., Yu, J., Gebre, M. S., Jacob-Dolan, C., Li, Z., Patel, S., Peter, L., Liu, J., Borducchi, E. N., . . . Barouch, D. H. (2021). Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. https://doi.org/10.1001/jama.2021.3645

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.